Disease Info Card

Diffuse Scleroderma

Information about Diffuse Scleroderma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Diffuse Scleroderma

Most recent studies have shown that Diffuse Scleroderma shares some biological mechanisms with arthritis, autoimmune-diseases, autoimmune-reaction, collagen-diseases, connective-tissue-diseases, dermatologic-disorders, dermatomyositis, fibrosis, hypertensive-disease, localized-scleroderma, lung-diseases, lupus-erythematosus-systemic, pulmonary-fibrosis, pulmonary-hypertension, raynaud-disease, rheumatism, rheumatoid-arthritis, scleroderma, sclerosis, sjogrens-syndrome.

Among the many pathways, these few ones have gauged particular interests from scientists studying Diffuse Scleroderma, and have been seen in publications frequently: Angiogenesis, Cell Activation, Cell Adhesion, Cell Proliferation, Coagulation, Cytokine Production, Excretion, Fibroblast Activation, Fibroblast Proliferation, Gastric Emptying, Immune Response, Localization, Pathogenesis, Peristalsis, Pigmentation, Reflex, Secretion, Vasoconstriction, Vasodilation, Wound Healing

Quite a number of genes have been found to play important roles in Diffuse Scleroderma, such as ACE, CALR, CCL2, CDSN, CRP, CTLA4, DMPK, EDN1, FN1, HLA-DQA1, IL2, IL4, IL6, PAH, PRB1, SS18L1, SSB, TNF, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.